Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03534037
Other study ID # 1-107-05-112
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date February 1, 2020
Est. completion date December 2021

Study information

Verified date April 2020
Source National Defense Medical Center, Taiwan
Contact Cheng-Wei Liu, M.D.
Phone 886-2-27642151
Email issac700319@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hyperuricemia is an additional risk factor for cardiovascular disease, associating with left ventricular diastolic dysfunction in individuals with metabolic syndrome. The effect of urate-lowering therapies on left ventricular diastolic dysfunction remains unclear. The study is conducted to investigate whether febuxostat or benzbromarone might improve left ventricular diastolic dysfunction in individuals with metabolic syndrome and hyperuricemia


Description:

Between 1, July 2018 and 31, Dec 2018, consecutive individuals with metabolic syndrome hyperuricemia are candidates of the present study. After the eligible candidates sign the informed consent, they will receive blood tests with a fasting time of 8 hours at least. The investigators will randomize the study participants by pre-specified random codes with a 1:1:1 ratio to the three groups. The study medication, febuxostat or benzbromarone, will be administered orally on the next day after transthoracic echocardiography is performed. The control group will only receive dietary control. All participant will receive transthoracic echocardiography and blood tests at baseline and at 3 months. The visit will be scheduled at baseline and at the 3rd month. The blood tests include high-sensitivity C-reactive protein, high-sensitivity interleukin-1 beta, high-sensitivity interleukin-6, tumor necrosis factor alpha, Dickkopf-related protein 3, galectin-3, ST2, fibroblast growth factor 23, xanthine oxidase activity, and thioredoxin.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date December 2021
Est. primary completion date December 2021
Accepts healthy volunteers No
Gender All
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria (all of the four criteria)

1. Aged between 40-75 years

2. Metabolic syndrome

3. Hyperuricemia, defined as a serum uric acid level of 7 mg/dl or more in men or 6 mg/dl or more in females, with a history of hyperuricemia within a year; or a serum uric acid level of 8 mg/dl or more in men or 7 mg/dl or more in females and it is hardly expected to be modified by dietary control; or persistent hyperuricemia after dietary control for 3 months

4. Not take any of urate-lowering therapies (benzbromarone, allopurinol, or febuxostat)

Exclusion Criteria:

1. pregnancy

2. hypersensitivity to febuxostat or benzbromarone

3. acute gout

4. a history of urinary tract stone

5. chronic kidney disease stage IV or V

6. valvular heart disease with moderate or severe regurgitation

7. left ventricular ejection fraction of 40% or less

8. hypertrophic cardiomyopathy or dilated cardiomyopathy or infiltrative cardiomyopathy or constrictive cardiomyopathy

9. a history of congenital heart disease

10. a history of pulmonary hypertension

11. chronic atrial fibrillation or significant arrhythmia

12. a history of intracardiac device implantation

13. uncontrolled hypertension (systolic blood pressure > 160mm Hg or diastolic blood pressure > 100 mm Hg)

14. alanine Aminotransferase > 3 times upper limit)

15. acute infection

16. suspected or diagnosed with malignancy

17. a history of autoimmune disease

18. limited to or dependent on daily activities

19. life expectancy less than a year

20. Acute coronary syndrome or received a percutaneous coronary intervention or received a coronary artery graft bypass surgery or stroke within 3 months

21. Diabetes with insulin treatment or glucagon-like peptide 1 receptor agonist treatment

22. Anemia (hemoglobin < 11 mg/dl in mem or <10mg/dl in women)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Febuxostat 40 mg
Febuxostat 40 mg orally per day plus dietary control only
Benzbromarone 50mg
Benzbromarone 50mg orally per day plus dietary control only
Other:
Control
Dietary control only

Locations

Country Name City State
Taiwan Tri-service General Hospital, songshan branch Taipei Songshan Dist.

Sponsors (1)

Lead Sponsor Collaborator
National Defense Medical Center, Taiwan

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of average E/e' the mean change of average E/e' in each group At day1 and at week 12
Primary Difference of average E/e' the mean difference of average E/e' between among three groups At day1 and at week 12
Primary Automate office blood pressure (AOBP) the mean difference of AOBP among three groups At day1 and at week 12
Secondary Change of xanthine oxidase activity the mean change of xanthine oxidase activity in each group At day1 and at week 12
Secondary Difference of xanthine oxidase activity the mean difference of xanthine oxidase activity among three groups At day1 and at week 12
Secondary Change of left ventricular mass index the mean change of left ventricular mass index in each group At day1 and at week 12
Secondary Difference of left ventricular mass index the mean difference of left ventricular mass index among three groups At day1 and at week 12
Secondary Change of tumor necrosis factor alpha the mean change of tumor necrosis factor alpha in each group At day1 and at week 12
Secondary Difference of tumor necrosis factor alpha the mean difference of tumor necrosis factor alpha among three groups At day1 and at week 12
Secondary Change of high-sensitivity interleukin-6 the mean change of high-sensitivity interleukin-6 in each group At day1 and at week 12
Secondary Difference of high-sensitivity interleukin-6 the mean difference of high-sensitivity interleukin-6 among three groups At day1 and at week 12
Secondary Change of thioredoxin the mean change of Thioredoxin in each group At day1 and at week 12
Secondary Difference of Thioredoxin the mean difference of Thioredoxin among three group At day1 and at week 12
Secondary Change of fibroblast growth factor 23 the mean Change of fibroblast growth factor 23 in each group At day1 and at week 12
Secondary Difference of fibroblast growth factor 23 the mean difference of fibroblast growth factor 23 among three groups At day1 and at week 12
Secondary Change of Dickkopf-related protein 3 the mean change of Dickkopf-related protein 3 in each group At day1 and at week 12
Secondary Difference of Dickkopf-related protein 3 the mean difference of Dickkopf-related protein 3 among three groups At day1 and at week 12
Secondary Change of galectin-3 the mean change of galectin-3 in each group At day1 and at week 12
Secondary Difference of galectin-3 the mean difference of galectin-3 among three groups At day1 and at week 12
Secondary Change of ST2 the mean change of ST2 in each group At day1 and at week 12
Secondary Difference of ST2 the mean difference of ST2 among three groups At day1 and at week 12
See also
  Status Clinical Trial Phase
Recruiting NCT04635202 - Effect of Elliptical Training on Metabolic Homeostasis in Metabolic Syndrome N/A
Completed NCT05343858 - Pilot Study to Evaluate the Effect of Two Microalgae Consumption on Metabolic Syndrome N/A
Completed NCT04053686 - An Intervention to Reduce Prolonged Sitting in Police Staff N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Recruiting NCT05040958 - Carotid Atherosclerotic Plaque Load and Neck Circumference
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Active, not recruiting NCT02500147 - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Phase 4
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Completed NCT03289897 - Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan N/A
Recruiting NCT05956886 - Sleep Chatbot Intervention for Emerging Black/African American Adults N/A
Completed NCT06057896 - Effects of Combined Natural Molecules on Metabolic Syndrome in Menopausal Women
Active, not recruiting NCT03613740 - Effect of Fucoxanthin on the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion Phase 2
Completed NCT04498455 - Study of a Prebiotic Supplement to Mitigate Excessive Weight Gain Among Physicians in Residency Phase 4
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT03697382 - Effect of Daily Steps on Fat Metabolism N/A
Completed NCT03241121 - Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome N/A
Completed NCT04509206 - Virtual Teaching Kitchen N/A
Completed NCT05124847 - TREating Pediatric Obesity N/A